Q-omics provides the consensus-scored TMEM218 profile across patient tissues and cancer cell-line models. TMEM218 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM218 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TMEM218 RNA expression shows 19,096 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where TMEM218 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM218 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM218 survival associations across molecular data types. TMEM218 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM218 RNA expression–survival associations across cancer types. High TMEM218 expression shows unfavorable associations in ACC, LIHC, KICH and LGG, but favorable associations in UCS and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM218 RNA expression.
This table summarizes TMEM218 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM218. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM218 shows lower tumor expression in KICH, THCA, LUAD and KIRC and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher TMEM218 RNA expression in normal versus tumor tissue (log2 FC = −1.800, t-test p < 0.001).
This table shows molecular features associated with TMEM218 in patient tissues and cancer cell lines. In patient samples, TMEM218 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM218 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
